To confirm the clinical utility of our classification scheme, future studies should carefully examine how these FOXA1 alteration classes govern outcomes in clinically relevant settings, including in primary prostate cancer, metastatic hormone-sensitive disease, and metastatic castration-resistant disease. This evidence concerns the gene FOXA1 and Familial prostate cancer.